Control Bionics Issues 50M Shares at $0.065, Secures $3.25M Capital
Control Bionics has secured $3.25 million through a discounted share placement, aiming to boost its assistive and neurotechnology product growth globally.
- Raised $3.25 million via placement of 50 million shares at $0.065 each
- Placement discounted 6.4% to recent VWAP and anchored by Reitham Equity GmbH
- Funds to accelerate commercialisation of NeuroNode and NeuroStrip technologies
- Focus on assistive communication, rehabilitation, and sports performance markets
- Shares to be issued on 5 December 2025, ranking equally with existing shares
Capital Raise to Fuel Growth
Control Bionics Limited (ASX – CBL), a pioneer in assistive neurotechnology, has successfully completed a $3.25 million private placement by issuing 50 million new shares at $0.065 each. This placement, representing a 6.4% discount to the recent volume-weighted average price, was anchored by European private equity investor Reitham Equity GmbH, a long-term supporter of the company.
The capital injection is designed to strengthen Control Bionics’ balance sheet and provide working capital to accelerate the commercial rollout of its core assistive technology products and emerging neurotechnology innovations. The company’s patented NeuroNode and the newer NeuroStrip devices are at the heart of this expansion, targeting markets ranging from assistive communication to rehabilitation and sports performance.
Innovating Assistive and Neurotechnology Solutions
Control Bionics’ NeuroNode technology is a wireless wearable device that detects subtle muscle signals via surface electromyography (EMG), enabling users with limited mobility to communicate and control computers more effectively. Integrated with eye gaze technology, it offers a unique three-modality control system that enhances speed and reduces fatigue for users.
The NeuroStrip, a miniaturised EMG device currently being commercialised, opens new avenues in health diagnostics, sports performance, and rehabilitation. Control Bionics’ strategic 22% stake in Neuro Elite Athletics further supports the growth of their NeuroBounce program in key markets such as the US and Australia.
Global Expansion and Market Potential
Operating across North America, Australia, Singapore, and Japan, Control Bionics is positioning itself to scale its global footprint. CEO Jeremy Steele highlighted the company’s commitment to delivering innovative neurotechnology solutions that enhance independence and quality of life worldwide. The fresh capital will underpin key commercial initiatives and help the company maintain momentum in competitive and rapidly evolving markets.
The new shares will rank equally with existing shares and are expected to be issued on 5 December 2025, marking a significant step in Control Bionics’ growth trajectory.
Bottom Line?
This capital raise sets the stage for Control Bionics to deepen its market presence, but investors will watch closely how effectively the funds translate into commercial success.
Questions in the middle?
- How will Control Bionics allocate the $3.25 million across its various commercial initiatives?
- What milestones can investors expect from the NeuroStrip and NeuroBounce programs in the near term?
- How might the share placement discount and dilution impact investor sentiment and share price performance?